- Home
- LZB vs VRDN Comparison
LZB vs VRDN Comparison
Compare LZB & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZB
- VRDN
- Stock Information
- Founded
- LZB 1927
- VRDN 2006
- Country
- LZB United States
- VRDN United States
- Employees
- LZB N/A
- VRDN N/A
- Industry
- LZB Home Furnishings
- VRDN Medical Specialities
- Sector
- LZB Consumer Discretionary
- VRDN Health Care
- Exchange
- LZB Nasdaq
- VRDN Nasdaq
- Market Cap
- LZB 1.7B
- VRDN 1.5B
- IPO Year
- LZB N/A
- VRDN N/A
- Fundamental
- Price
- LZB $42.77
- VRDN $20.14
- Analyst Decision
- LZB Hold
- VRDN Strong Buy
- Analyst Count
- LZB 1
- VRDN 10
- Target Price
- LZB N/A
- VRDN $37.25
- AVG Volume (30 Days)
- LZB 385.4K
- VRDN 1.1M
- Earning Date
- LZB 11-19-2024
- VRDN 11-12-2024
- Dividend Yield
- LZB 1.87%
- VRDN N/A
- EPS Growth
- LZB N/A
- VRDN N/A
- EPS
- LZB 2.81
- VRDN N/A
- Revenue
- LZB $2,060,908,000.00
- VRDN $302,000.00
- Revenue This Year
- LZB $2.59
- VRDN N/A
- Revenue Next Year
- LZB $3.95
- VRDN N/A
- P/E Ratio
- LZB $15.22
- VRDN N/A
- Revenue Growth
- LZB N/A
- VRDN N/A
- 52 Week Low
- LZB $30.68
- VRDN $11.40
- 52 Week High
- LZB $45.23
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- LZB 63.39
- VRDN 36.38
- Support Level
- LZB $40.65
- VRDN $22.40
- Resistance Level
- LZB $44.29
- VRDN $27.20
- Average True Range (ATR)
- LZB 0.96
- VRDN 1.36
- MACD
- LZB 0.47
- VRDN -0.41
- Stochastic Oscillator
- LZB 75.68
- VRDN 6.37
About LZB La-Z-Boy Incorporated
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; and Retail, which sells upholstered and case goods furniture to the end consumer. The majority of the company's revenue is derived from its Wholesale segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.